Urinary Tract Obstruction Treatment Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Urinary Tract Obstruction Treatment Devices Market by Product (Urinary Catheters [Indwelling/Foley Catheters, Intermittent Catheters, and External Catheters], Urinary Stents, Shock Wave Lithotripters [Intracorporeal and Extracorporeal], Ureteroscopes [Semi-Rigid and Flexible], Resectoscopes, Stone Retrieval Devices, Laser Therapy Systems, and Others), Indication (Cancers, Stones, Benign Prostatic Hyperplasia (BPH), Hydronephrosis, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a steady CAGR forecast till 2032 owing to the increasing cases of urological disorders and the rising product developmental activities across the globe.

The urinary tract obstruction treatment devices market is growing at a CAGR of 5.13% during the forecast period from 2025 to 2032. The urinary tract obstruction treatment devices market is growing significantly due to the increasing cases of urological disorders, including benign prostatic hyperplasia (BPH), kidney stones, urethral strictures, and tumors. Additionally, technological advancements in product development, growing preference for minimally invasive procedures are other factors that are expected to escalate the demand for urinary tract obstruction treatment devices during the forecast period from 2025 to 2032.

Urinary Tract Obstruction Treatment Devices Market Dynamics:

According to data from the Global Cancer Observatory (2024), in the year 2022, Europe accounted for 473,011 prostate cancer cases, and Asia accounted for 386,424 prostate cancer cases. Enlargement of the prostate gland due to cancer can compress the urethra or invade nearby tissues, leading to urinary retention or difficulty urinating. In advanced stages, prostate tumours may obstruct the bladder neck, urethra, or ureters, resulting in hydronephrosis (swelling of the kidneys due to urine build-up) and upper urinary tract obstruction, leading to complications that necessitate the use of stents, catheters, or other obstruction relief devices.

Furthermore, the same source stated that Asia accounted for 417,357 rectum cancer cases and Europe accounted for 181,701 rectum cancer cases. The rectum is located very close to the bladder, urethra, and ureters. When rectal cancer grows or spreads, it can compress or invade the urinary structures, thereby contributing to secondary urinary tract obstruction. As the global burden of these cancers increases, particularly in aging populations, the need for effective urinary tract obstruction treatment solutions is expected to rise in parallel, driving market growth.

The National Institute of Health (2024) reported that the prevalence of benign prostatic hyperplasia (BPH) is 50% to 60% for people in their 60s, increasing to 80% to 90% of those older than 70 years of age, globally. This age-related rise in BPH prevalence is directly linked to a growing patient population experiencing lower urinary tract symptoms and obstructive uropathy, conditions that require timely and effective medical intervention.

Additionally, the increasing activities among the key market players are further boosting the overall market of urinary tract obstruction treatment devices. For instance, in December 2022, CATHETRIX, an innovative developer of urinary (Foley) smart catheter fixation devices, commercially launched its catheter stabilizer aimed at preventing urinary tract infections (UTIs) and accidental Foley catheter extractions at Arab Health 2023, held from January to February 2023, in Dubai, UAE.

Therefore, the factors stated above collectively will drive the overall urinary tract obstruction treatment devices market during the forecast period from 2025 to 2032.

However, the disruption of surrounding tissue associated with hematuria and risks of stone fragment retention, among others, may limit their end-user base, thus acting as key constraints limiting the growth of the urinary tract obstruction treatment devices market.

Urinary Tract Obstruction Treatment Devices Market Segment Analysis:

Urinary Tract Obstruction Treatment Devices Market by Product (Urinary Catheters [Indwelling/Foley Catheters, Intermittent Catheters, and External Catheters], Urinary Stents, Shock Wave Lithotripters [Intracorporeal and Extracorporeal], Ureteroscopes [Semi-Rigid and Flexible], Resectoscopes, Stone Retrieval Devices, Laser Therapy Systems, and Others), Indication (Cancers, Stones, Benign Prostatic Hyperplasia (BPH), Hydronephrosis, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of urinary tract obstruction treatment devices, the extracorporeal shock wave lithotripters, a sub-category of shock wave lithotripters, are expected to have a significant revenue share in the year 2024. The rapid growth of this product category can be attributed to the features of the extracorporeal shock wave lithotripters. The main benefit of extracorporeal shock wave lithotripsy is the non-invasive treatment, as it does not involve any skin incisions or the use of any invasive surgical instruments. Instead, shock waves are utilized to shatter the stone into tiny fragments that flow through the ureter and out of the bladder. It also has other advantages, such as reduced pain, quick recovery time, and shorter hospital stays.

These are suited for small stones as well as certain stones present in the upper portion of the ureter. Moreover, multiple stones can also be treated with extracorporeal shock wave lithotripsy. Therefore, it is expected that with such advantages offered by the extracorporeal shock wave urinary tract obstruction treatment devices, this technology is expected to increase its penetration in the coming years.

Additionally, rising product development activities among market players are likely to drive the market for this category. For example, in May 2024, Huons Meditech made its debut as the first Korean company to participate in the American Urological Association 2024 Conference in Texas, where it unveiled its electromagnetic shock wave lithotriptor. The ASADAL-M1, equipped with patented extracorporeal shock wave technology, has demonstrated high efficacy in safely fragmenting urinary stones. The device has received approvals from both the U.S. Food and Drug Administration and the European Medical Device Regulation.

Therefore, owing to the above-mentioned factors, the demand for the extracorporeal shock wave lithotripters category upsurges, thereby the sub-category is expected to witness considerable growth, eventually contributing to the overall growth of the urinary tract obstruction treatment devices market during the forecast period from 2025 to 2032.

North America is expected to dominate the overall urinary tract obstruction treatment devices market:

Among all the regions, North America is expected to dominate the urinary tract obstruction treatment devices market in the year 2024. This is due to the increasing cases of kidney stones, growing prevalence of prostate cancer, underscoring the increased demand for effective management solutions enhanced by technological advancements. Additionally, the regulatory approvals, significant market presence of key companies, continued investment in healthcare infrastructure, and innovative product developments are expected to drive the market for urinary tract obstruction treatment devices during the forecast period from 2025 to 2032.

According to the American Urological Association (2024), nearly 1 in 11 individuals in the US experience kidney stones at some point in their lives, and evidence suggests that the incidence of kidney stones is increasing.

According to GLOBOCAN (2024), in 2022, the US accounted for 230,125 cases of prostate cancer, and Canada accounted for 25,560 cases of prostate cancer. Additionally, it further stated that by 2050, prostate cancer will reach 346,000 cases in the North American region.

The rising cases of kidney stones and prostate cancer are driving the demand for urinary tract obstruction treatment devices. As more individuals experience these conditions, there is a growing need for effective interventions to manage urinary blockages, making urinary tract obstruction treatment devices a rapidly expanding market.

Additionally, the rising product development activities by regulatory bodies in the region will further boost the market for urinary tract obstruction treatment devices. For example, in April 2024, Olympus Corporation announced FDA 510(k) clearance for its RenaFlex single-use ureteroscope system. RenaFlex offers access and visualization in the urinary tract to diagnose and treat urinary diseases and disorders, such as kidney stones.

Moreover, the presence of key players such as Boston Scientific Corporation, B. Braun Melsungen AG, and Cook, among others in the region with their strong distribution networks ensure widespread availability and accessibility of these devices increasing their revenue shares in the market is also a driving factor for the urinary tract obstruction treatment devices market as they hold a significant revenue share in the region.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America region in the urinary tract obstruction treatment devices market.

Urinary Tract Obstruction Treatment Devices Market key players:

Some of the key market players operating in the urinary tract obstruction treatment devices market include Boston Scientific Corporation, B. Braun Melsungen AG, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, Cook, BD, Teleflex Incorporated, STORZ MEDICAL AG, Olympus Corporation, EMS Urology, Dornier Medtech, Shockwave Medical Inc., ACE Medical Devices Pvt. Ltd., Applied Medical Resources Corporation, Richard Wolf GmbH, Stryker, Urocare Products, Inc., J and M Urinary Catheters LLC, Rocamed, and others.

Recent Developmental Activities in the Urinary Tract Obstruction Treatment Devices Market:

• In December 2024, Zenflow, a medical device company focused on minimally invasive solutions for urinary obstruction due to benign prostatic hyperplasia (BPH), announced the successful completion of a $24 million Series C funding round. The round featured new participation from Cook Medical alongside continued support from existing investors, including Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others.

Key takeaways from the urinary tract obstruction treatment devices market report study

• Market size analysis for the current urinary tract obstruction treatment devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the urinary tract obstruction treatment devices market
• Various opportunities available for the other competitors in the urinary tract obstruction treatment devices market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current urinary tract obstruction treatment devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for urinary tract obstruction treatment devices market growth in the future?

Target audience who can benefit from this urinary tract obstruction treatment device market report study

• Urinary tract obstruction treatment devices product providers
• Research organizations and consulting companies
• Urinary tract obstruction treatment devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in urinary tract obstruction treatment devices
• Various end-users who want to know more about the urinary tract obstruction treatment devices market and the latest developments in the urinary tract obstruction treatment devices market

Frequently Asked Questions for the Urinary Tract Obstruction Treatment Devices Market:

1. What are urinary tract obstruction treatment devices?

• The urinary tract obstruction treatment devices are devices used to treat obstruction that occurs in the course of urine from the kidney to the urethra.

2. What is the market for urinary tract obstruction treatment devices?

• The urinary tract obstruction treatment devices market is growing at a CAGR of 5.13% during the forecast period from 2025 to 2032.

3. What are the drivers for the urinary tract obstruction treatment devices market?

• The urinary tract obstruction treatment devices market is growing significantly due to the increasing cases of urological disorders including cancers and benign prostatic hyperplasia (BPH), rising geriatric population prone to such conditions, technological advancements in product development, growing preference of minimally invasive procedures are factors that are expected to escalate the demand for urinary tract obstruction treatment devices during the forecast period from 2025 to 2032.

4. Who are the key players operating in the urinary tract obstruction treatment devices market?

• Some of the key market players operating in the urinary tract obstruction treatment devices market include Boston Scientific Corporation, B. Braun Melsungen AG, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, Cook, BD, Teleflex Incorporated, STORZ MEDICAL AG, Olympus Corporation, EMS Urology, Dornier Medtech, Shockwave Medical Inc., ACE Medical Devices Pvt. Ltd., Applied Medical Resources Corporation, Richard Wolf GmbH, Stryker, Urocare Products, Inc., J and M Urinary Catheters LLC, Rocamed, and others.

5. Which region has the highest share in the urinary tract obstruction treatment devices market?

• This is due to the increasing cases of kidney stones, growing prevalence of prostate cancer, underscoring the increased demand for effective management solutions enhanced by technological advancements. Additionally, the regulatory approvals, significant market presence of leading companies, continued investment in healthcare infrastructure, and innovative product developments are expected to drive the market for urinary tract obstruction treatment devices during the forecast period from 2025 to 2032.

This product will be delivered within 2 business days.